Area of research
Hematology · Genetics
Research interest
Research focused on Myelodysplastic syndromes and Myeloid leukemia, with related work in Cancer research, Mutation, Chronic lymphocytic leukemia. Notable publications include 'An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults', 'Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both', and 'Chronic myeloid leukemia: reminiscences and dreams'.
Liquid biopsies for residual disease and recurrence
Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia
Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: A phase II, randomised, multicentre study comparing targeted therapy or immunotherapy with standard platinum-based chemotherapy
Genomic profiling of carcinomas of unknown primary (CUP) to support clinical decisions.
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer
Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia
Next Generation Sequencing of Castleman Disease and Follicular Dendritic Cell Sarcomas Associated with Castleman Disease
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
Chronic myeloid leukemia: reminiscences and dreams
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post‐ASH symposium